Thermo Fisher Scientific CD30 Monoclonal Antibody (Ber-H2)

Applications

Tested Dilution

Publications

Immunohistochemistry (IHC)

-

View 8 publications 8 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:50-1:100

-

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

Ber-H2

Immunogen

Co cell line established from a patient with Hodgkins disease of T-cell lineage. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CD30,uniProtId:P28908-1,ncbiNodeId:9606,antigenRange:1-595,antigenLength:595,antigenImageFileName:MA1-26282_CD30_P28908-1_House_mouse.svg,antigenImageFileNamePDP:MA1-26282_CD30_P28908-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

Conc. Not Determined

Storage buffer

tissue culture supernatant

Contains

0.05% sodium azide

Storage conditions

4° C, do not freeze

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_779677

Product Specific Information

MA1-26282 detects CD30 from human samples.

Target Information

CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. CD30 is a positive regulator of apoptosis, and has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkin`s lymphoma, Reed Sternberg cells and most Anaplastic Large Cell Lymphomas (ALCL). CD30 is also expressed by embryonal carcinomas.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.